Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1991-12-20
1993-03-02
Friedman, S. J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514460, A61K 3135, A61K 3140
Patent
active
051909707
ABSTRACT:
A method is provided for preventing or reducing the risk of or treating Type II diabetes by administering a cholesterol lowering drug, such as pravastatin, alone or in combintion with an ACE inhibitor, such as captopril, zofenopril, ceranapril, fosinopril, enalapril or lisinopril.
REFERENCES:
Yoshino G., et al, "Effect of CS-514, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on lipoprotein and apolipoprotein in plasma of hypercholesterolemic diabetics," Diabetes Res. Clin. Pract. (Netherlands), 1986, 2/3 (179-181).
Garg and Grundy, "Lovastatin Therapy for Cholesterol Lowering in Non-Insulin Dependent Diabetes Mellitus (NIDDM)," Clin. Res. (35, No. 3, 503A, 1987).
Garg et al, "Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus," New England J. Med, Jan. 14, 1988, (2) pp. 81-86.
Garg et al, "Treatment of dyslipidemia in non-insulin-dependent diabetes mellitus with lovastatin," Am. J. Cardiol. (US) Nov. 11, 1988, (15) pp. 44J-49J.
Gleeson et al, Clin. Res. (36, No. 1, 153A, 1988).
Yoshino et al, J. Jpn. Diabetes Soc. (Japan), 1988, 31/5 (385-391).
Steiner, G., Diabetes 1988: Proceedings of the 13th Congress of the International Diabetes Federation (1989, 553-560).
Zeller et al, Drug, Intell. Clin. Pharm. (22, No. 7-8, 542-5, 1988).
Yoshino et al, Atherosclerosis (Ireland), 1989, 75/1 (67-72).
Frishman et al, Med. Clin. North Am. (73, No. 2, 437-48, 1989).
Johnson et al (Merck), Clin. Pharmacol. Ther. (45, No. 2, 141, 1989).
Ronca et al (Merck), Clin. Res. (37, No. 1, 100A, 1989).
Pollare, T., et al, "A Comparison of the Effects of hydrochlorothiazide and Captopril on Glucose and Lipid Metabolism in Patients with Hypertension," New England Journal of Medicine, 321:868-873 (Sep. 28) 1989.
Rett, K., et al, "Role of angiotensin-converting enzyme inhibitors in early anti-hypertensive treatment in non-insulin dependent diabetes mellitus," Postgrad Med. J. 1989a/ 64 (Suppl. 3):69-73.
Rett, K., et al, "Angiotensin converting enzyme inhibitors in diabetes: experimental and human experience," Postgrad. Med. J. (U.K.) 1986 62/Suppl. 1 (59-64).
Jauch, K., et al, "Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus," Eur. J. Clin. Invest. (U.K.), 1987, 17/5 (448-454).
Bergman Michael
Pan Henry Y.
E. R. Squibb & Sons Inc.
Friedman S. J.
Rodney Burton
LandOfFree
Method for preventing onset of or treating Type II diabetes empl does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preventing onset of or treating Type II diabetes empl, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preventing onset of or treating Type II diabetes empl will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-126914